"Endometrial Neoplasms" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Tumors or cancer of ENDOMETRIUM, the mucous lining of the UTERUS. These neoplasms can be benign or malignant. Their classification and grading are based on the various cell types and the percent of undifferentiated cells.
| Descriptor ID |
D016889
|
| MeSH Number(s) |
C04.588.945.418.948.585 C13.351.500.852.762.200 C13.351.937.418.875.200
|
| Concept/Terms |
Endometrial Neoplasms- Endometrial Neoplasms
- Endometrial Neoplasm
- Neoplasm, Endometrial
- Neoplasms, Endometrial
Endometrial Carcinoma- Endometrial Carcinoma
- Carcinoma, Endometrial
- Carcinomas, Endometrial
- Endometrial Carcinomas
- Endometrial Cancer
- Cancer, Endometrial
- Cancers, Endometrial
- Endometrial Cancers
- Endometrium Cancer
- Cancer, Endometrium
- Cancers, Endometrium
- Cancer of the Endometrium
- Carcinoma of Endometrium
- Endometrium Carcinoma
- Endometrium Carcinomas
- Cancer of Endometrium
- Endometrium Cancers
|
Below are MeSH descriptors whose meaning is more general than "Endometrial Neoplasms".
Below are MeSH descriptors whose meaning is more specific than "Endometrial Neoplasms".
This graph shows the total number of publications written about "Endometrial Neoplasms" by people in this website by year, and whether "Endometrial Neoplasms" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 6 | 1 | 7 |
| 1995 | 10 | 0 | 10 |
| 1996 | 6 | 2 | 8 |
| 1997 | 6 | 2 | 8 |
| 1998 | 2 | 4 | 6 |
| 1999 | 4 | 0 | 4 |
| 2000 | 2 | 3 | 5 |
| 2001 | 5 | 1 | 6 |
| 2002 | 4 | 1 | 5 |
| 2003 | 12 | 5 | 17 |
| 2004 | 11 | 2 | 13 |
| 2005 | 17 | 4 | 21 |
| 2006 | 20 | 3 | 23 |
| 2007 | 15 | 1 | 16 |
| 2008 | 17 | 1 | 18 |
| 2009 | 24 | 2 | 26 |
| 2010 | 22 | 3 | 25 |
| 2011 | 17 | 1 | 18 |
| 2012 | 21 | 3 | 24 |
| 2013 | 42 | 4 | 46 |
| 2014 | 27 | 2 | 29 |
| 2015 | 35 | 4 | 39 |
| 2016 | 32 | 4 | 36 |
| 2017 | 24 | 2 | 26 |
| 2018 | 16 | 2 | 18 |
| 2019 | 38 | 0 | 38 |
| 2020 | 30 | 7 | 37 |
| 2021 | 19 | 0 | 19 |
| 2022 | 19 | 0 | 19 |
| 2023 | 38 | 1 | 39 |
| 2024 | 20 | 0 | 20 |
To return to the timeline,
click here.
Below are the most recent publications written about "Endometrial Neoplasms" by people in Profiles.
-
Long-Term Follow-up of Levonorgestrel Intrauterine Device for Atypical Hyperplasia and Early Endometrial Cancer Reveals Relapse Characterized by Immune Exhaustion. Clin Cancer Res. 2024 Nov 15; 30(22):5073-5082.
-
Real-world use of immune checkpoint inhibitors in advanced or recurrent endometrial cancer. Int J Gynecol Cancer. 2024 Nov 04; 34(11):1719-1728.
-
Comparative analysis of hormonal therapy in low-grade endometrial stromal sarcoma: A retrospective study. Gynecol Oncol. 2024 Dec; 191:143-149.
-
2009 International Federation of Gynecology and Obstetrics (FIGO) stage IIIA endometrial cancer: oncologic outcomes based on involvement of adnexa, serosa, or both. Int J Gynecol Cancer. 2024 Oct 07; 34(10):1580-1587.
-
Uterine-Conserving Treatment Options for Atypical Endometrial Hyperplasia and Early Endometrial Cancer. Curr Oncol Rep. 2024 Nov; 26(11):1367-1379.
-
ENGOT-en11/GOG-3053/KEYNOTE-B21: a randomised, double-blind, phase III study of pembrolizumab or placebo plus adjuvant chemotherapy with or without radiotherapy in patients with newly diagnosed, high-risk endometrial cancer. Ann Oncol. 2024 Nov; 35(11):968-980.
-
Financial Improvements From Short Course Adjuvant Vaginal Cuff Brachytherapy in Early Endometrial Cancer Compared With Standard of Care, "SAVE" Trial. Pract Radiat Oncol. 2024 Nov-Dec; 14(6):e500-e506.
-
Translating biological insights into improved management of endometrial cancer. Nat Rev Clin Oncol. 2024 Nov; 21(11):781-800.
-
Comprehensive molecular characterization of early stage grade 3 endometrioid endometrial adenocarcinoma. Gynecol Oncol. 2024 Oct; 189:138-145.
-
ENGOT-EN20/GOG-3083/XPORT-EC-042 - A phase III, randomized, placebo-controlled, double-blind, multicenter trial of selinexor in maintenance therapy after systemic therapy for patients with p53 wild-type, advanced, or recurrent endometrial carcinoma: rationale, methods, and trial design. Int J Gynecol Cancer. 2024 Aug 05; 34(8):1283-1289.